Novartis Wants Tighter Grip Over Its Indian Ops; Announces Open Offer To Up Stake To 90%
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Swiss-headquartered Novartis announced a tender offer to buy an additional stake of up to 39 percent in its majority-owned Indian subsidiary Novartis India. The Swiss drug maker, which markets popular pain killer Voveran (diclofenac) in India among several other products, would raise its stake in the subsidiary to nearly 90 percent if the open offer for the shares passes successfully
You may also be interested in...
Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent
Pharma plans further launches of its patented products in emerging market.
Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent
Pharma plans further launches of its patented products in emerging market.
Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent
MUMBAI - After Novartis and Mylan, it's now Pfizer's turn to increase its equity holding in its Indian operations. In an announcement to the Bombay Stock Exchange, Pfizer said it has decided to acquire an additional stake of 33.77 percent in Pfizer India through an open offer from public shareholders at a price of 675 rupees per share ($13.23)